SCHEMBL3979017

SCHEMBL3979017

Clc1ncnc2cc(-c3ccncc3)sc12

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.67
RAB9A P51151 1/20 0.67
KMT2A Q03164 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
IKBKB O14920 1/20 0.50
TYK2 P29597 1/20 0.46
MAP3K8 P41279 5/20 0.45
STK17B O94768 3/20 0.45
FLT1 P17948 3/20 0.43
KIT P10721 1/20 0.43
AXL P30530 1/20 0.43
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
CDC7 O00311 2/20 0.42
DBF4 Q9UBU7 2/20 0.42
EGFR P00533 2/20 0.41
BRAF P15056 1/20 0.39
GSK3B P49841 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2879120 0.87 NPC1 (0.67) NPC1RAB9AKMT2ATDP1IKBKB
SCHEMBL15504606 0.84 RAB9A (0.68) NPC1RAB9AKMT2ATDP1IKBKB
SCHEMBL17268775 0.84 NPC1 (0.72) NPC1RAB9AKMT2ATDP1IKBKB
SCHEMBL5475238 0.83 NPC1 (0.58) NPC1RAB9AKMT2ATDP1IKBKB
SCHEMBL5641499 0.83 NPC1 (0.58) NPC1RAB9AKMT2ATDP1IKBKB
SCHEMBL15703517 0.80 NPC1 (1.00) NPC1RAB9AKMT2ATDP1IKBKB
SCHEMBL5787192 0.79 NPC1 (0.61) NPC1RAB9AKMT2ATDP1IKBKB
SCHEMBL5242191 0.78 CDC7 (0.43) NPC1RAB9AKMT2ATDP1IKBKB
SCHEMBL31227788 0.77 CDC7 (0.42) NPC1RAB9AKMT2ATDP1TYK2
SCHEMBL5312477 0.76 NPC1 (0.51) NPC1RAB9AKMT2ATDP1IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008074749-A9 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2009-05-07 WO claimed
US-20090118276-A1 THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS WYETH (US) 2009-05-07 US disclosed
WO-2009059272-A1 THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS WYETH (US) 2009-05-07 WO disclosed
WO-2007056208-A2 N-ARYLALKYL-THIENOPYRIMIDIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2007-05-18 WO disclosed
WO-2007056208-A2 N-ARYLALKYL-THIENOPYRIMIDIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2007-05-18 WO disclosed
US-20070099941-A1 N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed
US-20070099941-A1 N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118276-A1 THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS BRAF, ARAF, RAF1 NPC1 4417/4885RAB9A 1149/4885KMT2A 1956/4885
US-20070099941-A1 N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP10, CASP3, CASP4 NPC1 2719/4885RAB9A 1912/4885KMT2A 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.